132 related articles for article (PubMed ID: 18172306)
21. Clinical perspectives of bispecific antibodies in cancer.
de Gast GC; van de Winkel JG; Bast BE
Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853
[No Abstract] [Full Text] [Related]
22. ROCKETS - a novel one-for-all toolbox for light sheet microscopy in drug discovery.
Mueller JPJ; Dobosz M; O'Brien N; Abdoush N; Giusti AM; Lechmann M; Osl F; Wolf AK; Arellano-Viera E; Shaikh H; Sauer M; Rosenwald A; Herting F; Umaña P; Colombetti S; Pöschinger T; Beilhack A
Front Immunol; 2023; 14():1034032. PubMed ID: 36845124
[TBL] [Abstract][Full Text] [Related]
23. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer.
Shen J; Qian N; Xu G; Dou X; An Y; Yang C; Liu Y; Liu Y; Pan X; Wang J; Bai G; Chen H; Zhu X; Gao X; Zhou G; Xu Q
Int Immunopharmacol; 2024 Jun; 137():112424. PubMed ID: 38878486
[TBL] [Abstract][Full Text] [Related]
24. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors.
Weddell J
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1726-1737. PubMed ID: 36710368
[TBL] [Abstract][Full Text] [Related]
25. FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer.
Mullard A
Nat Rev Drug Discov; 2024 May; ():. PubMed ID: 38789515
[No Abstract] [Full Text] [Related]
26. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818
[TBL] [Abstract][Full Text] [Related]
28. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
29. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
[TBL] [Abstract][Full Text] [Related]
30. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
[TBL] [Abstract][Full Text] [Related]
31. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
32. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
Yamamoto K; Trad A; Baumgart A; Hüske L; Lorenzen I; Chalaris A; Grötzinger J; Dechow T; Scheller J; Rose-John S
Biochem J; 2012 Jul; 445(1):135-44. PubMed ID: 22509934
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.
Michalk I; Feldmann A; Koristka S; Arndt C; Cartellieri M; Ehninger A; Ehninger G; Bachmann MP
PLoS One; 2014; 9(4):e95517. PubMed ID: 24751697
[TBL] [Abstract][Full Text] [Related]
34. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
35. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
Ahmed M; Cheng M; Cheung IY; Cheung NK
Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
37. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
[TBL] [Abstract][Full Text] [Related]
38. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
[TBL] [Abstract][Full Text] [Related]
39. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
Golay J; D'Amico A; Borleri G; Bonzi M; Valgardsdottir R; Alzani R; Cribioli S; Albanese C; Pesenti E; Finazzi MC; Quaresmini G; Nagorsen D; Introna M; Rambaldi A
J Immunol; 2014 Nov; 193(9):4739-47. PubMed ID: 25267972
[TBL] [Abstract][Full Text] [Related]
40. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Teachey DT; Rheingold SR; Maude SL; Zugmaier G; Barrett DM; Seif AE; Nichols KE; Suppa EK; Kalos M; Berg RA; Fitzgerald JC; Aplenc R; Gore L; Grupp SA
Blood; 2013 Jun; 121(26):5154-7. PubMed ID: 23678006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
